GMT EIGHT - OPPORTUNITIES IN CHINA

CG SERVICES (06098) announced its interim results, with a profit attributable to shareholders of approximately 950 million yuan, a decrease of 4.6% compared to the same period last year.

Country Garden Services (06098) announced its interim results for 2026, with revenue of approximately 24.5 billion yuan, a year-on-year increase of 5.7%; the profit attributable to shareholders of the company is approximately 950 million yuan, a year-on-year decrease of 4.6%; the core net profit attributable to shareholders is 1.6185 billion yuan, a year-on-year increase of 3.2%; basic earnings per share are 29.16 cents.

GIORDANO INT'L (00709) will distribute a mid-term dividend of HKD 0.067 per share on October 2.

Giordano International (00709) announced that it will distribute an interim dividend of HK$0.067 per share for the six months ending on June 30, 2026, on October 2, 2026.

BJ ENT WATER (00371) will distribute a mid-term dividend of HKD 0.0554 per share on October 26.

Beijing Enterprises Water Group (00371) announced that the company will distribute an interim dividend of HK$0.0554 per share for the six months ending June 30, 2026, on October 26, 2026.

ASIA FINANCIAL (00662) will distribute an interim dividend of HK$0.07 per share on October 8.

Asia Financial (00662) announced that the company will distribute an interim dividend of HK$0.07 per share on October 8, 2026.

CONSUN PHARMA (01681) will distribute an interim dividend of HK$0.38 per share on October 8.

Kang Chen Pharmacy (01681) announced that it will distribute an interim dividend of HK$0.38 per share for the six months ending June 30, 2026, on October 8, 2026.

CHINA OVERSEAS (00688) will distribute an interim dividend of HKD 0.23 per share on October 5.

China Overseas Development (00688) announced that the company will distribute an interim dividend of HK$0.23 per share on October 5, 2026.

ANTA SPORTS (02020) released its interim results, with a profit attributable to shareholders of 9.487 billion yuan, an increase of 34.9% year-on-year.

Anta Sports (02020) announced its interim results for 2026, reporting revenue of RMB 43.507 billion, an increase of 12.9% year-on-year; net profit attributable to shareholders was RMB 9.487 billion, up 34.9% year-on-year; basic earnings per share were RMB 3.42, and an interim dividend of HKD 0.151 per share is proposed.

ANTA SPORTS (02020) will distribute an interim dividend of HK$1.51 per share on September 22.

Anta Sports (02020) announced that it will pay an interim dividend of HK$1.51 per share on September 22, 2026.

CHINA RES POWER (00836) will distribute an interim dividend of HK$0.321 per share on October 30.

China Resources Power (00836) announced that it will distribute an interim dividend of HKD 0.321 per share on October 30, 2026.

ASIA FINANCIAL (00662) announced its interim results, reporting a net profit attributable to shareholders of HKD 666 million, an increase of 57.29% year-on-year.

Asia Financial (00662) released its interim results for 2026, reporting insurance revenue of HKD 1.532 billion, a year-on-year increase of 5.52%; the profit attributable to shareholders was HKD 666 million, up 57.29% year-on-year; basic earnings per share were HKD 0.721; and it proposed an interim dividend of HKD 0.07 per share.

CHINA OVERSEAS (00688) announced its interim results, with a profit attributable to shareholders of approximately HKD 7.03 billion, a decrease of 18.24% year-on-year. A dividend of 23 Hong Kong cents per share will be distributed.

China Overseas Development (00688) announced its mid-year results for 2026, with revenue of approximately 97.6 billion yuan, a year-on-year increase of 17.28%; the company's attributable profit to shareholders was about 7.03 billion yuan, a year-on-year decrease of 18.24%; earnings per share were 0.64 yuan, and the interim dividend was 23 Hong Kong cents per share.

SIHUAN PHARM (00460) announced its interim results, with a net profit attributable to shareholders of 225 million yuan, an increase of 119% year-on-year, and continues to focus on the dual-driver long-term development strategy of "aesthetic medicine + innovative drugs."

Sihuan Pharmaceutical (00460) announced its performance for the six months ending June 30, 2026. During this period, the group achieved total revenue of 1.161 billion yuan, an increase of 1.3% year-on-year; profit attributable to shareholders was 225 million yuan, an increase of 119% year-on-year; basic earnings per share were 2.49 cents.

COFCO JOYCOME (01610) announced its interim results, reporting an owner's attributable loss of 1.553 billion yuan after fair value adjustments of biological assets, a reversal from profit to loss year-on-year.

China National Cereals, Oils and Foodstuffs Corporation (01610) announced its mid-year results for 2026, with operating revenue of RMB 8.736 billion, a year-on-year decrease of 2.5%. After fair value adjustments of biological assets, the loss attributable to the company's owners amounted to RMB 1.553 billion, a shift from profit to loss compared to the same period last year.

SSY GROUP (02005) will distribute an interim dividend of HKD 0.055 per share on September 24.

Shijiuyuan Group (02005) announced that the company will distribute a mid-term dividend of HK$0.055 per share for the six months ended June 30, 2026, on September 24, 2026.

SSY GROUP (02005) released its interim results, with profit attributable to shareholders of HK$320 million, an increase of 12.99% year-on-year.

Shanghai Pharmaceuticals Holding Co., Ltd. (02005) announced its mid-term results for 2026, reporting a revenue of HKD 2.361 billion, an increase of 9.94% year-on-year; the profit attributable to equity holders of the company was HKD 320 million, reflecting a year-on-year increase of 12.99%; basic earnings per share were HKD 0.1107, with a proposed interim dividend of HKD 0.055 per share.

CONSUN PHARMA (01681) released its interim results, with shareholders profit amounting to 595 million yuan, an increase of 19.5% year-on-year. Sales of kidney-related products grew approximately 18.1% compared to the same period last year.

Kangchen Pharmaceutical (01681) announced its results for the six months ending June 30, 2026. During the reporting period, the group achieved revenue of 1.785 billion RMB, an increase of 13.8% year-on-year; the profit attributable to equity shareholders was 595 million RMB, an increase of 19.5% year-on-year; basic earnings per share were 0.71 RMB; and an interim dividend of HKD 0.38 per share is proposed.

Anta brand leads high-quality growth, ANTA SPORTS (02020) achieves record-breaking mid-term performance.

Anta Sports achieved revenue of 43.51 billion yuan in the first half of 2026, a year-on-year increase of 12.9%; operating profit margin improved by 0.7 percentage points to 27%, reaching a nearly seven-year high.

XUANZHUBIO-B (02575) released its interim results, with revenue of 69.4 million yuan, an increase of 288.1% year-on-year, advancing through four main lines in synergy.

Xuan Bamboo Bio-B (02575) reported its performance for the six months ending June 30, 2026, during which the group achieved revenue of 69.4 million yuan, a year-on-year increase of 288.1%; the loss attributable to the parent company was 75.34 million yuan, a year-on-year improvement of 32.07%; basic loss per share was 0.15 yuan.

CHINA RES POWER (00836) released its mid-term results, with a profit attributable to shareholders of HKD 6.649 billion, a decrease of 15.53% year-on-year.

China Resources Power Holdings Company Limited (00836) announced its interim results for 2026, reporting a revenue of HK$54.977 billion, an increase of 9.37% year-on-year; the profit attributable to equity holders was HK$6.649 billion, a decrease of 15.53% year-on-year; the basic earnings per share were HK$1.28, and an interim dividend of HK$0.321 per share is proposed.

BJ ENT WATER (00371) announced its interim results, with a profit attributable to shareholders of 688 million yuan, a year-on-year decrease of 23.31%.

Beijing Enterprises Water Group (00371) announced its performance for the six months ended June 30, 2026. During this period, the group recorded operating revenue of RMB 9.871 billion, a year-on-year decrease of 5.62%; the profit attributable to shareholders was RMB 688 million, a year-on-year decrease of 23.31%; basic earnings per share were 6.43 cents; and a mid-term dividend of 5.54 Hong Kong cents per share is proposed.

A-shares Midday | Three Major Indices All Closed Higher, Brokerages, Non-ferrous Metals, and Nuclear Fusion Lead the Surge

The A-share market rebounded in the morning, showing a pattern of "collective increase in indices, widespread rise in individual stocks, with large financials and non-ferrous metals leading the way."

From the strong mid-year results, we can see the changing growth logic of ZIBUYU (02420): the TikTok business saw a year-on-year surge of over 600%, gradually reducing its dependence on a single platform.

Zibuyu is evolving from relying on a single platform to becoming a fashion brand cross-border e-commerce company that develops in a balanced manner across multiple channels.

Waterdrop, Inc. ADR Class A (WDH.US) aims to address the clinical recruitment challenges in extensive-stage small cell lung cancer through Yi Fan Pharmaceutical, setting a new standard for services.

Yifan Pharmaceutical of Waterdrop Company solves the recruitment challenges for clinical trials of extensive-stage small cell lung cancer.

The unified index for medical insurance pathology has officially launched, enabling precise medical care through seamless code interoperability.

On August 14, 2026, the National Healthcare Security Administration officially issued the "Medical Insurance Pathology Cloud Index" coding specification.

SHIYUE DAOTIAN (09676) reported revenue of 3.814 billion yuan in the first half of the year, leading to a model-driven valuation reassessment.

Both income and profits have increased, with the growth model continuously releasing results. The dividend yield exceeds 8%. Household food leader October Rice Field (09676) showcases its performance strength to the market once again.

The balance of whether the Bank of Korea will raise interest rates hangs in the balance until the last moment, with economists greatly divided over whether to take action this Thursday.

The Bank of Korea will weigh whether to continue raising interest rates, as economic growth and inflation remain strong.

The Hong Kong dollar interbank offered rate developed unevenly, with the one-month rising by 1.155 basis points to 2.79411%.

On August 26, Hong Kong dollar interbank offered rates developed in a mixed manner, with the one-month interbank offered rate related to mortgage loans reported at 2.79411%.

The Token Factory layout has exceeded performance expectations, and the value reassessment of PHANCY (06682), positioned at the nerve center of the industry, is imminent.

This mid-term financial report is undoubtedly a compelling "touchstone." Paradigm Intelligence's "Token Factory" layout has already achieved substantial and unexpected results in terms of performance, becoming the core growth engine driving the company's fundamental explosion.

Ceasefire negotiations between the U.S. and Iran make significant progress.

Iran and Oman have reached an agreement to temporarily restart navigation in the Strait of Hormuz; both countries have committed to continue negotiations in the coming months to finalize a more "permanent" solution.

BINHAI INV (02886) Performance Shines: Sales Volume Increases, Profit Improvement May Drive Stock Price Rebound

Binhai Investment (02886) is a city gas stock that is relatively undervalued by the market.

BINHAI INV (02886) reports impressive interim results as new projects gradually achieve scale, with the valuation expected to improve.

The group achieved simultaneous growth in both revenue and profit, demonstrating the resilience of its core business. At the same time, leveraging the resources of its two major shareholders, it is accelerating its transformation into a comprehensive energy supplier, opening up medium to long-term growth opportunities.

"The brutal summer" prophecy takes a sharp turn! Castle Securities turns bullish on U.S. bonds, betting on a decline in long-term yields.

Frank Flett now believes that the risk balance has shifted in favor of a rebound in U.S. Treasuries. He points out that the short positions in the bond market are overly crowded, while inflation data is improving.

AAC TECH (02018) CFO Guo Dan: Revenue is expected to grow by double digits in 2026, and the AI new business is expected to exceed 8 billion next year.

Guo Dan stated that, facing pressure from the external market environment, the management remains cautiously optimistic about the operations for the entire year, expecting double-digit revenue growth for the year and a steady increase in gross margin from a base of 22.4%.

Bank of America: The U.S. semiconductor sector may drop another 10%, but there is now an "enhanced buying" opportunity. These eight chip stocks are the top choices for low-entry positions.

Bank of America stated that several factors may lead to a decline in chip stocks, but they also create buying opportunities.

Anthropic throws out a $30 trillion TAM "super narrative," sprinting towards a $2 trillion IPO with "rocket-like growth."

According to reports, the artificial intelligence company Anthropic is expected to tell investors that its total addressable market (TAM) exceeds $30 trillion, higher than SpaceX's previous estimate of $28.5 trillion.

Three dissenting votes from the FOMC + support from four regional Federal Reserve board members for interest rate hikes reveal divisions within the Federal Reserve.

Before the Federal Reserve's interest rate meeting in July, the boards of four of the twelve Federal Reserve Banks voted to support raising the discount rate.

A-share opening report | Shanghai Composite Index opened down 0.20% but turned positive, with the paper and biotechnology sectors leading the gains.

On August 26, the A-shares opened with Shanghai weaker and Shenzhen stronger, showing index divergence.

Revenue surged by 70.4%, intelligent body business doubled, and HaiZhi Technology (02706) has entered the period of large-scale realization in theAI.

On August 25, Haizhi Technology (02706) announced its unaudited interim results for the six months ending June 30, 2026.

Bessenet's intervention in the bond market has faced stern warnings from its "mentor" Druckenmiller: artificially suppressing yields is a "deferred subsidy," which will be unsustainable in the long run.

U.S. Treasury Secretary Scott Bessent's recent interventions in the bond market have led to a slight retreat in long-term yields, but they have also sparked a growing number of questions.

METIS TECHBIO-P (07666) 2026 Interim Report: Half-year revenue surpasses last year's total by 47%, achieving leapfrog growth and leading the implementation of AI4S in life sciences.

On August 25, Jitai Technology disclosed its mid-year performance for 2026. During the reporting period, the company's operating revenue reached 154 million yuan, a substantial increase of 13,339% year-on-year, exceeding last year's total revenue by 47%.

NVIDIA Corporation (NVDA.US) Ends Seven-Day Decline Before Earnings; Institutions Say: Simply Exceeding Profit Expectations Isn't Enough, Capital Roadmap Becomes Key.

Nvidia not only needs to deliver earnings data that exceed expectations, but also needs to provide the market with specific details regarding capital allocation and the maintenance of investment plans.

A-shares Pre-Market Report | Easing of US-Iran Diplomacy Leads to a Plunge in Oil Prices, Optical Communication and Storage Concepts Counterattack, Alibaba's US Stocks Surge Temporarily

The United States and Iran have reached a consensus on the terms of a ceasefire agreement, which includes free navigation in the Strait of Hormuz, and Brent crude oil temporarily fell by 6%.

Brokerage Morning Meeting Highlights | Positive Outlook on Investments in the Power Industry Chain

CITIC Construction Investment believes in the positive investment outlook for the power industry chain; Huatai Securities contends that negative feedback from capital has yet to materialize; China International Capital Corporation believes that the supply-demand pattern of tantalum and niobium is being reshaped, leading to a revaluation of strategic value.

DEEPZERO (02723) has signed a strategic cooperation memorandum of understanding with Deloitte China.

Deep Intelligence (02723) announced that the company has signed a strategic cooperation memorandum with Deloitte Consulting (Shanghai) Co., Ltd. (Deloitte China). Deloitte China has long been committed to serving large enterprises in complex transformations and has accumulated extensive experience in AI strategic planning, industry insights, data governance, and organizational change.

GENFLEET-B(02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, which will explore multiple treatment regimens including monotherapy, combination with EGFR monoclonal antibodies, or chemotherapy.

JinFang Pharmaceutical-B (02595) announced that GFH375 has entered a Phase II study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutation, including three treatment regimens: monotherapy, combination with EGFR monoclonal antibody (Cetuximab), or combination with chemotherapy (Pemetrexed).

VIX futures have sounded the alarm in advance! The U.S. midterm elections in November are expected to become a window of high volatility for U.S. stocks.

Traders in the equity derivatives market have begun preparing for a potential increase in volatility around the November U.S. midterm elections.

MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

Manulife Financial-S (00945) announced that it will distribute a second quarter dividend of CAD 0.485 per share on September 21, 2026.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

Boreton (01333) announced that based on the information currently available to the board and a preliminary assessment of the groups unaudited consolidated management accounts for the six months ending June 30, 2026 (the "period"), it is expected that the group will incur a loss of approximately RMB 80 million to RMB 90 million during this period, representing a decrease of approximately 45.93% to 51.67% compared to the loss of approximately RMB 174 million incurred in the same period of 2025.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.

Kangfang Biotech (09926) announced that the interim analysis results of the randomized, controlled, double-blind, multicenter Phase III clinical study (AK112309/HARMONi-GI1) comparing the company's independently developed world-first bispecific antibody YidaFang (Ivosidenib, PD-1/VEGF) combined with chemotherapy regimen against Durvalumab (PD-L1) combined with chemotherapy regimen for first-line treatment of advanced biliary tract cancer, evaluated by the independent data monitoring committee (IDMC), demonstrated that the study achieved the primary endpoint of overall survival (OS), yielding statistically significant and clinically meaningful positive results; the study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).

ZAI LAB (09688) released its interim results, reporting a net loss of $102 million, with R&D expenses increasing by 14% year-on-year to $127 million.

Zai Ding Medical (09688) announced its results for the six months ending June 30, 2026, during which the group achieved a total revenue of $206 million; a net loss of $102 million; and a basic loss per share of $0.09.

Latest

18/08

Citigroup: Initiates "Buy" rating for Zijin Mining International (02259), optimistic about production growth and gold price outlook.

18/08

Ganfeng Lithium: Progress on Subsidiary's Involvement in Investment Limited Partnership Matters

18/08

Zhichun Technology (603690.SH) plans to transfer part of its shares in the affiliated company Weidun Crystal Phosphate for 20 million yuan.

18/08

Xiamen Releases Twelve Measures to Promote Exchange and Cooperation with Taiwan

18/08

Yuncong Technology: The company is deeply involved in the national standardized pilot project "Shanghai Virtual-Real Integration Embodied Intelligence Training Ground" and the "Humanoid Robot Qilin Training Ground" project.

Seeking Coverage

Being Writer

Exploring Cooperation